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Cutaneous malignant melanoma (CMM) is a neoplasm
which has always evoked scientific interest out of proportion
to its frequency. Over the past decades, CMM has shown the
most rapidly increasing neoplasm in yearly incidence. Such
increased incidence outweighed the moderate improvements
in therapy, causing a global increase in mortality. The disease
progresses from the primary CMM (stages I and II) to a
locoregional disease (stage III) and a disseminated metastatic
disease (stage IV). Surgery represents the mainstay often
curative for thin primary CMM that have not yet given rise
to distant metastases. Beyond that stage, the therapeutic
options remain unsatisfactory. Indeed, according to the
American Joint Committee on Cancer (AJCC), the percent-
age of patients with metastatic melanoma surviving 1-year
ranges from 33 to 62%.
The present special issue contains ten papers focused
on new developments in the field of CMM progression
toward the metastatic disease. Two papers deal with imaging
procedures used for detecting metastases and with unusual
clinical evolution of metastases. Two papers focus on serum
biomarkers, and one covers the interpretation of CMM cell
migration along specific skin structures. A series of four
papers regard peculiar aspects of molecular biology associ-
ated with the CMM metastatic process. Finally, one paper
addresses some recent developments in biologic treatments.
In the paper entitled “Review of diagnostic imaging
modalities for the surveillance of melanoma patients,” Y. Xing
et al. present a meta-analysis evaluating the current state
of imaging modalities for detecting CMM metastases. They
compare the sensitivity, specificity, and positive predictive
values of ultrasonography, computed tomography (CT),
positron emission tomography (PET), and CT-PET com-
bined. Ultrasonography was found to be the most sensitive
and specific for detecting lymph node metastases, and PET-
CT was the most sensitive and specific for detecting distant
metastases.
In the paper entitled “Smouldering malignant melanoma
and metastatic dormancy,” G. E. Pie´rard et al. explore two
peculiar evolutions of the versatile CMM metastatic disease,
namely, the smouldering CMM and the CMM dormancy.
A long disease-free interval (CMM dormancy) occasionally
occurs before the surge of overt metastases. The so-called
CMM smouldering phenomenon refers to the condition
where regional metastases wax and wane for long periods of
time on restricted skin regions. Local micrometastases often
predict sentinel lymph node involvement but they do not
always reflect progression of the primary CMM to full-blown
visceral metastatic competence. A combination of factors
impacts the versatile CMM metastasic progression. The
putative factors include the heterogeneity and phenotypic
variability of CMM cells, the presence of CMM stem cells and
CMM cells engaged in an amplification proliferation pool, as
well as the host immune response, and possibly the induction
of a particular stromal structure and vascularity.
The papers entitled “Biomarkers as key contributors in
treating malignant melanoma metastases,” by C. Ferreira de
Souza et al., and “A synopsis of serum biomarkers in cutaneous
melanoma patients,” by P. Vereecken et al., describe CMM
serum biomarkers. A poor correlation exists between
biomarkers discovered by basic research and data from
clinical trials. It remains that LDH and the S100 B protein
levels are correlated with poor prognosis in the American
2 Dermatology Research and Practice
Joint Committee of Cancer (AJCC) stage III/IV CMM pa-
tients.
The paper entitled “Thigmotropism of malignant mela-
noma cells,” by P. Quatresooz et al., is an original view of the
migration process of CMM cells. During CMM progression
including incipient metastasis, neoplastic cells follow some
specific migration paths inside the skin. In particular, they
progress along the dermoepidermal basement membrane,
the hair follicles, the sweat glands, nerves, and the near
perivascular space. These features evoke the thigmotropism
phenomenon defined as a contact-sensing growth of cells.
This process is likely connected to modulation in cell
tensegrity (control of the cell shape). These specifically
located paucicellular aggregates of CMM cells do not appear
to be involved in the tumorigenic growth phase, but rather
they participate in the so-called “accretive” growth model.
In the paper entitled “Molecular dermatopathology in ma-
lignant melanoma,” M. A. Reginster et al. summarize and
update some methods of molecular diagnosis applicable
to CMM. Sensitive techniques are available for detecting
specific DNA and RNA sequences by molecular hybridiza-
tion. Cytogenetics highlights the pathogenesis of atypical
melanocytic neoplasms with emphasis on the activation
of the mitogen-activated protein kinase (MAPK) signalling
pathway during the initiation step of the neoplasms. A
minority of CMM families have mutations in the tumour
suppressor gene p16 or CDKN2A. In addition, somatic
mutations in p16, p53, BRAF, and cKIT are present in CMM.
Genome-wide scan analyses on CMM indicate positive
associations for genes involved in melanocytic naevi, but
MM is likely caused by a variety of common low penetrance
genes.
The paper entitled “miRNAs and melanoma: how are they
connected?” by A. Taveira da Cruz et al. is focused on the
epigenetic and mRNA control by microRNAs (miRNAs).
miRNAs are essential in the processing and control of many
biological responses, in particular in cancer development.
Some molecular pathways are frequently disrupted in CMM,
and miRNAs probably have a decisive role on that. New
findings about miRNAs are presented in CMM, underlying
both some epigenetic processes, and the promise of miRNAs
in diagnosis and therapy of CMM.
In the paper entitled “RAS/RAF/MEK/ERK and P13K/
PTEN/AKT signalling inmalignant melanoma progression and
therapy,” I. Yajima et al. discuss molecular changes associ-
ated with CMM progression. In human CMM, the RAS/
RAF/MEK/ERK (MAPK) and the P13K/PTEN/AKT (AKT)
signalling pathways represent two major pathways that are
constitutively activated through genetic alterations. Muta-
tions of RAF, RAS, and PTEN contribute to anti-apoptosis,
abnormal proliferation, angiogenesis, and invasion for CMM
development and progression. This paper reviews the MAPK
and AKT signalling networks associated with CMM develop-
ment and progression.
In the paper entitled “Targeting the cellular signalling:
BRAF inhibition and beyond for the treatment of metastatic
malignant melanoma,” F. Ades and O. Metzger-Filho report
important translational researches having identified mecha-
nisms in malignant transformation, invasion, and progres-
sion. Signalling pathways can be abnormally activated by
oncogenes. The identification of oncogenic mutated kinases
in CMM provides an opportunity for new target therapies.
The CMM dependence of BRAF-mutated kinase allowed the
development of inhibitors that produced major responses
in clinical trials. This represents the beginning of a novel
class of drugs in metastatic CMM; the identification of the
transduction signalling networking and other “druggable”
kinases is currently under active investigations. In this re-
view, the ongoing research on cellular signalling inhibition,
resistance mechanisms, and strategies to overcome treatment
failure is discussed in depth.
In the paper entitled “Ipilimumab, a promising immun-
otherapy with increased overall survival in metastatic mela-
noma?”, G. E. Pie´rard et al. review new advances in metastatic
CMM biotreatment. The therapeutic options remain limited
for advanced CMM, and those directed to the neoplastic
cells have not brought major survival advantage so far.
Immunotherapy is another targeted option. Ipilimumab,
a monoclonal antibody directed to CTLA-4 present on
cytotoxic T cells, boosts immunity, particularly its anti-
CMM activity. Under treatment, the overall survival of pa-
tients with CMM metastases is moderately but significantly
increased. In some instances, the immunorelated adverse
eﬀects are severe and life-threatening.
We hope this special issue will not only help to clarify the
understanding of the CMM metastatic process, but also will
reinforce the development of better treatment modalities for
disseminated CMM.
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